305 related articles for article (PubMed ID: 35844561)
1. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
2. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.
Coria LM; Saposnik LM; Pueblas Castro C; Castro EF; Bruno LA; Stone WB; Pérez PS; Darriba ML; Chemes LB; Alcain J; Mazzitelli I; Varese A; Salvatori M; Auguste AJ; Álvarez DE; Pasquevich KA; Cassataro J
Front Immunol; 2022; 13():844837. PubMed ID: 35296091
[TBL] [Abstract][Full Text] [Related]
3. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
4. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
[TBL] [Abstract][Full Text] [Related]
5. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
6. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
7. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
8. Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice.
Firmino-Cruz L; Dos-Santos JS; da Fonseca-Martins AM; Oliveira-Maciel D; Guadagnini-Perez G; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Vicente Santos AC; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Rossi-Bergmann B; Vale AM; Filardy AD; Silva JL; de Oliveira AC; Gomes AMO; de Matos Guedes HL
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016193
[TBL] [Abstract][Full Text] [Related]
9. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
Front Immunol; 2021; 12():803647. PubMed ID: 35095889
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity.
Kim E; Attia Z; Woodfint RM; Zeng C; Kim SH; Steiner HE; Shukla RK; Liyanage NPM; Ghimire S; Li J; Renukaradhya GJ; Satoskar AR; Amer AO; Liu SL; Cormet-Boyaka E; Boyaka PN
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34353890
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
13. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
Liu H; Zhou C; An J; Song Y; Yu P; Li J; Gu C; Hu D; Jiang Y; Zhang L; Huang C; Zhang C; Yang Y; Zhu Q; Wang D; Liu Y; Miao C; Cao X; Ding L; Zhu Y; Zhu H; Bao L; Zhou L; Yan H; Fan J; Xu J; Hu Z; Xie Y; Liu J; Liu G
Vaccine; 2021 Nov; 39(48):7001-7011. PubMed ID: 34750014
[TBL] [Abstract][Full Text] [Related]
14. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
15. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; O'Farrell L; Noel R; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
J Control Release; 2022 Jul; 347():476-488. PubMed ID: 35577151
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
18. Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models.
Nazarian S; Olad G; Abdolhamidi R; Motamedi MJ; Kazemi R; Kordbacheh E; Felagari A; Olad H; Ahmadi A; Bahiraee A; Farahani P; Haghighi L; Hassani F; Hajhassan V; Nadi M; Sheikhi A; Salimian J; Amani J
Mol Immunol; 2022 Sep; 149():107-118. PubMed ID: 35802999
[TBL] [Abstract][Full Text] [Related]
19. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection
Luan N; Li T; Wang Y; Cao H; Yin X; Lin K; Liu C
Front Immunol; 2022; 13():882856. PubMed ID: 35464483
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability.
Huang H; Zhou Z; Xiong X; Liu Z; Zheng X; Quan Q; Yu M
Front Public Health; 2022; 10():976686. PubMed ID: 36684881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
